Toggle navigation
Home
Feed
Channels
Profile
Home
Feed
Channels
Profile
Medspoke's Talks
Medspoke
Medspoke
Leukemia
Published October 6, 2026
Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnos...
October 7, 2026
Medspoke
Medspoke
Leukemia
Published October 6, 2026
00:00
--:--
KT-253, a highly potent and selective MDM2 protein degrader, eliminates malignant myelofibrosis s...
October 7, 2026
Share
KT-253, a highly potent and selective MDM2 protein degrader, eliminates malignant myelofibrosis stem/progenitor cells.
https://www.medspoke.co/channel_journal?id=683&tap_id=15195
Copy Link
Email
X
Bluesky
WhatsApp
LinkedIn
Facebook
Reddit
Medspoke
Medspoke
Journal of the European Academy of Dermatology and Venereology (JEADV)
Published October 6, 2026
Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab.
October 7, 2026
Why are you reporting this TALK?
